[From The New York Times, July 16, 2018] “On July 3, 1981, this newspaper wrote about a “rare cancer” killing gay men in New York and California. Though few knew it, what followed would be a generation-defining battle: for attention, for legitimacy, for our very lives. Today, after 37 years, we finally have a proven pathway […]
Why Don’t More Americans Use PrEP? Read More »
[From tctMD, July 13, 2018] “People with HIV are more than twice as likely to develop cardiovascular disease than those without the virus, according to the results of a new review and meta-analysis. CVD attributable to HIV has more than doubled globally over the past two decades, from 0.36% in 1990 to 0.92% in 2015,
Global Burden of HIV-Related CVD Has Tripled Over Two Decades Read More »
[From France24, July 12, 2018] “The AIDS Association of France has launched a nationwide campaign to raise awareness of PrEP, an antiviral drug that protects against HIV. Although little known in France, the medication has proven effective in countries like the US and UK.” For more, click here.
PrEP pill to prevent HIV remains little known in France Read More »
[From OttawaCitizen, July 12, 2018] “MISSISSAUGA, Ontario — Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for Biktarvy™ (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIKTARVY combines the potency of a novel integrase strand
[From AIDSmap, July 11, 2018] “Research is urgently needed to provide clear recommendations on breastfeeding to mothers with HIV who have an undetectable viral load on antiretroviral treatment, a group of researchers say in the journal The Lancet HIV.” For more, click here.
